AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com

StockNews.com downgraded shares of AC Immune (NASDAQ:ACIU) from a buy rating to a hold rating in a research note released on Tuesday.

Separately, HC Wainwright reaffirmed a buy rating and set a $16.00 target price on shares of AC Immune in a research note on Wednesday, September 18th.

AC Immune Stock Performance

NASDAQ ACIU opened at $3.38 on Tuesday. The stock has a market cap of $334.28 million, a P/E ratio of -4.90 and a beta of 1.24. AC Immune has a fifty-two week low of $2.20 and a fifty-two week high of $5.14. The stock has a 50 day simple moving average of $3.42 and a two-hundred day simple moving average of $3.39.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million. Sell-side analysts predict that AC Immune will post -0.89 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

Several hedge funds have recently made changes to their positions in ACIU. Platinum Investment Management Ltd. lifted its position in AC Immune by 14.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock valued at $7,578,000 after buying an additional 193,123 shares during the period. Avidity Partners Management LP lifted its position in AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock valued at $22,345,000 after acquiring an additional 1,499,280 shares during the period. BVF Inc. IL lifted its position in AC Immune by 96.2% during the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock valued at $72,856,000 after acquiring an additional 7,142,857 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in AC Immune by 96.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock worth $56,000 after acquiring an additional 9,334 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in AC Immune by 315.6% in the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares during the period. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.